PhRMA Report on Clinical Trials in NC Details Benefits to Local Patients, Economy, Medical Science

DURHAM, N.C. -- Working with institutions in the Triangle and throughout North Carolina, the nation’s biopharmaceutical research companies have conducted over 6,000 clinical trials of new medicines in North Carolina since 1999, says a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report, “Research in Your Backyard: Pharmaceutical Clinical Trials in North Carolina,” was released recently at a news conference at Quintiles world headquarters located in Durham near the Research Triangle Park.
*****
NCTechNews is published by Innovative Public Relations, Inc. (www.innovativepublicrelations.com), a Research Triangle-based consultancy providing PR and media relations services to help clients achieve their business development and organizational goals. NCTechNews supplements quality reporting provided by respected media outlets throughout North Carolina and the United States.
*****

 Representative Nelson Dollar, of Cary, welcomed advocates, scientists, economic developers, and clinical trials patients from around the region to the event. Additional speakers included Tom Pike, Quintiles CEO, Paula Brown Stafford, President of Clinical Development at Quintiles, Jack Bailey, Senior Vice President of Policy, Payers, and Vaccines at GSK, Thomas Hardaway, Senior Regional Director at PhRMA, Sam Taylor, President of NCBIO, and Chris Brown, Vice President of Research and Graduate Education at the University of North Carolina. Also speaking at the event was clinical trial participant and Quintiles employee, Tess Brennan.

The report shows that over 895 of the state’s clinical trials have targeted the most debilitating chronic diseases, including cancer, diabetes, heart disease and stroke, with over 400 of the chronic disease medicine trials still active and recruiting patients throughout North Carolina. For some patients, clinical trials can be an alternative therapy to discuss with their health care providers and clinicians conducting the trials.

“As a leader of outsourced clinical trial management and the largest service provider today, Quintiles plays a vital part in the clinical research ecosystem in North Carolina and around the world – fueling new therapies and high-quality jobs,” said Tom Pike, CEO of Quintiles, who served as master of ceremonies.

“Every day we are engaged in helping our biopharma customers improve their probability of success and improve patient outcomes. When our customers succeed, we make progress toward our vision of bringing people and knowledge together for a healthier world.”

The economic benefits of collaborations with biopharmaceutical companies include the support of the companies for more than 226,000 jobs in North Carolina in 2011, with thousands in the Triangle, according to the most recent data. The companies also supported the generation of $50.3 billion in statewide economic activity.

“Cutting-edge clinical research is happening right now in the Triangle and across North Carolina. Clinical trials are just one part of the development of live saving medicines. These are industries looking for participants that in turn will grow jobs, develop cures, and create a better quality of life for everyone,” said Representative Nelson Dollar.

The report presented a number of resources for persons interested in clinical trials, including local companies, patient advocacy groups, internet resources, as well as public-private partnerships such as those at the Duke University Medical Center in Durham, UNC at Chapel Hill School of Medicine and the Wake Forest University School of Medicine in Winston-Salem.

The report also focused on the “I’m In” campaign, a collaborative program launched by PhRMA and the National Quality Forum in March of 2014. The program is designed to accelerate participation of diverse populations in clinical trials. Currently, African Americans are 12 percent of the population, but account for just 5 percent of clinical research participants; and Hispanics make up 16 percent of the population, but only 1 percent of clinical research participants.

About PhRMA: The Pharmaceutical Research and Manufacturers of America, represents the country’s leading biopharmaceutical researchers and biotechnology companies. Headquartered in Washington, DC, with offices in leading biopharmaceutical research communities, PhRMA advocates in the U.S. and around the world on public policy issues critical to the discovery and development of innovative medicines. These priorities include the increased complexity and risk of the research and development process; continued need for investment in R&D; broad access to and appropriate use of medicines; increased value for today's patients; and the continued importance of strong intellectual property incentives for new medicines.

About PhRMA
PhRMA represents the country’s leading biopharmaceutical researchers and biotechnology companies.  Headquartered in Washington, DC, with offices in leading biopharmaceutical research communities, PhRMA advocates in the U.S. and around the world on public policy issues critical to the discovery and development of innovative medicines. These priorities include the increased complexity and risk of the research and development process; continued need for investment in R&D; broad access to and appropriate use of medicines; increased value for today's patients; and the continued importance of strong intellectual property incentives for new medicines.